Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial

被引：0
|
作者：
Ahn, M. -J. [1 ]
Delmonte, A. [2 ]
Ghosh, S. [3 ]
Hochmair, M. [4 ,5 ]
Yang, T. -Y. [6 ]
Yang, J. C. -H. [7 ,8 ]
Han, J. -Y. [9 ]
Hansen, K. Holmskov [10 ]
Wu, Y. [11 ]
Wan, Y. [11 ]
Lin, H. M. [11 ]
Kretz, J. [12 ]
Hupf, B. [11 ]
Kurec, A. M. [13 ]
Churchill, E. N. [14 ]
Fram, R. J. [11 ]
Cabasag, C. J. [15 ]
Goriya, V. [16 ]
Zhao, Y. [17 ]
Gemmen, E. [18 ]
Campelo, M. R. Garcia [19 ,20 ]
机构：
[1] Sungkyunkwan Univ, Dept Med Oncol, Samsung Med Ctr, Div Hematol,Sch Med, Seoul, South Korea
[2] IRCCS Ist Romagnolo Studio Tumori Dino Amadori I, Cesena, Italy
[3] Guys & St Thomas NHS Fdn Trust, London, England
[4] Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria
[5] Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria
[6] Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan
[7] Natl Taiwan Univ Hosp, Taipei, Taiwan
[8] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan
[9] Natl Canc Ctr, Goyang, South Korea
[10] Odense Univ Hosp, Odense, Denmark
[11] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[12] Takeda Pharmaceut Int AG, Glattpark Opfikon Zurich, Zurich, Switzerland
[13] Takeda Pharmaceut Int Singapore Emerging Markets, Singapore, Singapore
[14] Takeda Pharmaceut USA Inc, Lexington, MA USA
[15] IQVIA RDS France, Courbevoie, France
[16] IQVIA RDS France, Courbevoie, France
[17] IQVIA RDS Shanghai Co Ltd, Shanghai, Peoples R China
[18] IQVIA Falls Church, Falls Church, VA USA
[19] Univ Hosp Coruna, Dept Med Oncol, La Coruna, Spain
[20] Biomed Res Inst INIBIC A Coruna, La Coruna, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Brigatinib; ALK plus NSCLC; ALK TKI;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.12B.03
引用
收藏
页码：S200 / S200
页数：1
相关论文
共 50 条
  • [1] Real-World Treatment Patterns and Effectiveness in Patients with ALK plus Advanced NSCLC Treated with 1L ALK TKIs
    Chen, Y.
    Lin, H. M.
    Wan, Y.
    Yin, Y.
    Wu, Y.
    Hernandez, L.
    Danes, C.
    Churchill, E. N.
    Dimou, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S641 - S641
  • [2] Brigatinib vs Crizotinib in patients (pts) with ALK inhibitornaive advanced ALK plus NSCLC from the phase 3 ALTA-1L trial
    Griesinger, F.
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Campelo, Garcia M. R.
    Kim, D. -W.
    Bearz, A.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 75 - 76
  • [3] Brigatinib vs crizotinib in ALK TKI-naive ALK plus NSCLC: final results from ALTA-1L
    Popat, Sanjay
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James
    Han, Ji-Youn
    Hochmair, Maximilian
    Lee, Ki Hyeong
    Delmonte, Angelo
    Garcia Campelo, Maria
    Kim, Dong-Wan
    Griesinger, Frank
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott
    Tiseo, Marcello
    Lin, Huamao
    Liu, Yuyin
    Vranceanu, Florin
    Camidge, D.
    LUNG CANCER, 2022, 165 : S27 - S28
  • [4] Brigatinib versus crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: results from the phase 3 ALTA-1L trial
    Califano, R.
    Camidge, D.
    Kim, H. -R.
    Ahn, M. -J.
    Yang, J.
    Han, J. -Y.
    Hochmair, M.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D. -W.
    Griesinger, F.
    Felip, E.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Popat, S.
    LUNG CANCER, 2020, 139 : S59 - S60
  • [5] Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI-naive ALK plus NSCLC: Final results from ALTA-1L
    Popat, S.
    Kim, H. R.
    Ahn, M-J.
    Yang, J. C.
    Han, J-Y.
    Hochmair, M. J.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D-W.
    Griesinger, F.
    Felip, E.
    Califano, R.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Lin, H. M.
    Liu, Y.
    Vranceanu, F.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S954 - S955
  • [6] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK plus NSCLC from ALTA-1L
    Yang, James C. H.
    Kim, Hye R.
    Ahn, Myung-Ju
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki H.
    Delmonte, Angelo
    Garcia Campelo, Maria R.
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott
    Tiseo, Marcello
    Haney, Jeff
    Kerstein, David
    Popat, Sanjay
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC in the ALTA-1L and J-ALTA studies
    Camidge, D. Ross
    Sugawara, Shunichi
    Kondo, Masashi
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Kudou, Kentarou
    Asato, Takayuki
    Liu, Yuyin
    Vranceanu, Florin
    Fram, Robert J.
    Ohe, Yuichiro
    Popat, Sanjay
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
    Camidge, R.
    Kim, H. R.
    Ahn, M.
    Yang, J. C.
    Han, J.
    Lee, J.
    Hochmair, M.
    Li, J. Y.
    Chang, G.
    Lee, K.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
  • [9] Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
    Camidge, D. Ross
    Sugawara, Shunichi
    Kondo, Masashi
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James C. H.
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Kudou, Kentarou
    Asato, Takayuki
    Hupf, Bradley
    Vranceanu, Florin
    Fram, Robert J.
    Ohe, Yuichiro
    Popat, Sanjay
    LUNG CANCER, 2025, 201
  • [10] Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trial
    Camidge, R.
    Kim, H. R.
    Ahn, M-J.
    Yang, J. C-H.
    Han, J-Y.
    Hochmair, M. J.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D-W.
    Griesinger, F.
    Felip, E.
    Califano, R.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Popat, S.
    ANNALS OF ONCOLOGY, 2019, 30
12345